Dapiglutide Explained
| Drug Name: | Dapiglutide |
| Synonyms: | ZP 7570 |
| Legal Status: | Investigational |
| Cas Number: | 2296814-85-0 |
| Unii: | J43GMI6IYW |
| C: | 192 |
| H: | 302 |
| N: | 46 |
| O: | 57 |
Dapiglutide (formerly ZP 7570) is a dual GLP-1 and GLP-2 receptor agonist developed by Zealand Pharma.[1] [2]
Notes and References
- Reiner . Johannes . Berlin . Peggy . Held . Jascha . Thiery . Johanna . Skarbaliene . Jolanta . Griffin . Jonathan . Russell . Wayne . Eriksson . Per-Olof . Berner-Hansen . Mark . Ehlers . Luise . Vollmar . Brigitte . Jaster . Robert . Witte . Maria . Lamprecht . Georg . 2. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel . Journal of Parenteral and Enteral Nutrition . July 2022 . 46 . 5 . 1107–1118 . 10.1002/jpen.2286. free . 34705281 .
- Olsen . Minna B. . HöVelmann . Ulrike . Griffin . Jon . Knudsen . Kim M. . Eriksson . Per-Olof . Agersnap . Mikkel A. . 2. 335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects . Diabetes . 1 June 2022 . 71 . Supplement_1 . 10.2337/db22-335-OR. 249256542 .
